Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 365

1.

Treatment and long-term outcomes in pituitary carcinoma: a cohort study.

Santos-Pinheiro F, Penas-Prado M, Kamiya-Matsuoka C, Waguespack SG, Mahajan A, Brown P, Shah K, Fuller GN, Mccutcheon I.

Eur J Endocrinol. 2019 Jul 1. pii: EJE-18-0795.R2. doi: 10.1530/EJE-18-0795. [Epub ahead of print]

PMID:
31349217
2.

Multicenter study demonstrates radiomic features derived from magnetic resonance perfusion images identify pseudoprogression in glioblastoma.

Elshafeey N, Kotrotsou A, Hassan A, Elshafei N, Hassan I, Ahmed S, Abrol S, Agarwal A, El Salek K, Bergamaschi S, Acharya J, Moron FE, Law M, Fuller GN, Huse JT, Zinn PO, Colen RR.

Nat Commun. 2019 Jul 18;10(1):3170. doi: 10.1038/s41467-019-11007-0.

3.

Mutations of the MAPK/TSC/mTOR pathway characterize periventricular glioblastoma with epithelioid SEGA-like morphology-morphological and therapeutic implications.

Georgescu MM, Li Y, Islam MZ, Notarianni C, Sun H, Olar A, Fuller GN.

Oncotarget. 2019 Jun 18;10(40):4038-4052. doi: 10.18632/oncotarget.27005. eCollection 2019 Jun 18.

4.

Coexisting FGFR3 p.K650T mutation in two FGFR3-TACC3 fusion glioma cases.

Ballester LY, Moghadamtousi SZ, Leeds NE, Huse JT, Fuller GN.

Acta Neuropathol Commun. 2019 Apr 29;7(1):63. doi: 10.1186/s40478-019-0721-7. No abstract available.

5.

REST-DRD2 mechanism impacts glioblastoma stem cell-mediated tumorigenesis.

Marisetty AL, Lu L, Veo BL, Liu B, Coarfa C, Kamal MM, Kassem DH, Irshad K, Lu Y, Gumin J, Henry V, Paulucci-Holthauzen A, Rao G, Baladandayuthapani V, Lang FF, Fuller GN, Majumder S.

Neuro Oncol. 2019 Jun 10;21(6):775-785. doi: 10.1093/neuonc/noz030.

PMID:
30953587
6.

Prospective Clinical Sequencing of Adult Glioma.

Zheng S, Alfaro-Munoz K, Wei W, Wang X, Wang F, Eterovic AK, Shaw KRM, Meric-Bernstam F, Fuller GN, Chen K, Verhaak RG, Mills GB, Yung WKA, Weathers SP, de Groot JF.

Mol Cancer Ther. 2019 May;18(5):991-1000. doi: 10.1158/1535-7163.MCT-18-1122. Epub 2019 Mar 29.

PMID:
30926639
7.

RBM10 truncation in astroblastoma in a patient with history of mandibular ameloblastoma: A case report.

Majd NK, Metrus NR, Santos-Pinheiro F, Trevino CR, Fuller GN, Huse JT, Chung C, Ketonen L, Anderson MD, Penas-Prado M.

Cancer Genet. 2019 Feb;231-232:41-45. doi: 10.1016/j.cancergen.2019.01.001. Epub 2019 Jan 9.

PMID:
30803556
8.

Guiding the first biopsy in glioma patients using estimated Ki-67 maps derived from MRI: conventional versus advanced imaging.

Gates EDH, Lin JS, Weinberg JS, Hamilton J, Prabhu SS, Hazle JD, Fuller GN, Baladandayuthapani V, Fuentes D, Schellingerhout D.

Neuro Oncol. 2019 Mar 18;21(4):527-536. doi: 10.1093/neuonc/noz004.

PMID:
30657997
9.

ATRX protein loss and deregulation of PI3K/AKT pathway is frequent in pilocytic astrocytoma with anaplastic features.

Olar A, Tran D, Mehta VP, Reinhardt A, Manekia JH, Garnovskaya M, Ellezam B, Luthra R, Sulman EP, Mohila CA, Campbell GA, Powell SZ, Fuller GN, Aldape KD, Adesina AM.

Clin Neuropathol. 2019 Mar/Apr;38(2):59-73. doi: 10.5414/NP301105.

PMID:
30499772
10.

Osteopontin mediates glioblastoma-associated macrophage infiltration and is a potential therapeutic target.

Wei J, Marisetty A, Schrand B, Gabrusiewicz K, Hashimoto Y, Ott M, Grami Z, Kong LY, Ling X, Caruso H, Zhou S, Wang YA, Fuller GN, Huse J, Gilboa E, Kang N, Huang X, Verhaak R, Li S, Heimberger AB.

J Clin Invest. 2019 Jan 2;129(1):137-149. doi: 10.1172/JCI121266. Epub 2018 Nov 19.

11.

Pazopanib in patients with von Hippel-Lindau disease: a single-arm, single-centre, phase 2 trial.

Jonasch E, McCutcheon IE, Gombos DS, Ahrar K, Perrier ND, Liu D, Robichaux CC, Villarreal MF, Weldon JA, Woodson AH, Pilie PG, Fuller GN, Waguespack SG, Matin SF.

Lancet Oncol. 2018 Oct;19(10):1351-1359. doi: 10.1016/S1470-2045(18)30487-X. Epub 2018 Sep 17.

PMID:
30236511
12.

Primary Leptomeningeal Oligodendroglioma, IDH-Mutant, 1p/19q-Codeleted.

Ballester LY, Dunbar E, Guha-Thakurta N, Henson JW, Chandler H, Watkins J, Fuller GN.

Front Neurol. 2018 Aug 27;9:700. doi: 10.3389/fneur.2018.00700. eCollection 2018.

13.

REST overexpression in mice causes deficits in spontaneous locomotion.

Lu L, Marisetty A, Liu B, Kamal MM, Gumin J, Veo B, Cai Y, Kassem DH, Weng C, Maynard ME, Hood KN, Fuller GN, Pan ZZ, Cykowski MD, Dash PK, Majumder S.

Sci Rep. 2018 Aug 14;8(1):12083. doi: 10.1038/s41598-018-29441-3.

14.

Clinical significance of FBXO17 gene expression in high-grade glioma.

Du D, Yuan J, Ma W, Ning J, Weinstein JN, Yuan X, Fuller GN, Liu Y.

BMC Cancer. 2018 Jul 31;18(1):773. doi: 10.1186/s12885-018-4680-3.

15.

A Coclinical Radiogenomic Validation Study: Conserved Magnetic Resonance Radiomic Appearance of Periostin-Expressing Glioblastoma in Patients and Xenograft Models.

Zinn PO, Singh SK, Kotrotsou A, Hassan I, Thomas G, Luedi MM, Elakkad A, Elshafeey N, Idris T, Mosley J, Gumin J, Fuller GN, de Groot JF, Baladandayuthapani V, Sulman EP, Kumar AJ, Sawaya R, Lang FF, Piwnica-Worms D, Colen RR.

Clin Cancer Res. 2018 Dec 15;24(24):6288-6299. doi: 10.1158/1078-0432.CCR-17-3420. Epub 2018 Jul 27.

PMID:
30054278
16.

Atypical Alexander disease with dystonia, retinopathy, and a brain mass mimicking astrocytoma.

Machol K, Jankovic J, Vijayakumar D, Burrage LC, Jain M, Lewis RA, Fuller GN, Xu M, Penas-Prado M, Gule-Monroe MK, Rosenfeld JA, Chen R, Eng CM, Yang Y, Lee BH, Moretti PM; Undiagnosed Diseases Network, Dhar SU.

Neurol Genet. 2018 Jul 20;4(4):e248. doi: 10.1212/NXG.0000000000000248. eCollection 2018 Aug. No abstract available.

17.

Spinal Epidermoid Tumors: Case Report and Review of the Literature.

Beechar VB, Zinn PO, Heck KA, Fuller GN, Han I, Patel AJ, Ropper AE.

Neurospine. 2018 Jun;15(2):117-122. doi: 10.14245/ns.1836014.007. Epub 2018 Jun 19.

18.

The Role of Fibrinogen-Like Protein 2 on Immunosuppression and Malignant Progression in Glioma.

Latha K, Yan J, Yang Y, Gressot LV, Kong LY, Manyam G, Ezhilarasan R, Wang Q, Sulman EP, Eric Davis R, Huang S, Fuller GN, Rao A, Heimberger AB, Li S, Rao G.

J Natl Cancer Inst. 2019 Mar 1;111(3):292-300. doi: 10.1093/jnci/djy107.

19.

Pilot study of dovitinib in patients with von Hippel-Lindau disease.

Pilié P, Hasanov E, Matin SF, Woodson AHH, Marcott VD, Bird S, Slack RS, Fuller GN, McCutcheon IE, Jonasch E.

Oncotarget. 2018 May 4;9(34):23390-23395. doi: 10.18632/oncotarget.25171. eCollection 2018 May 4.

20.

Embryonal Tumor with Multilayered Rosettes, C19MC-Altered: Clinical, Pathological, and Neuroimaging Findings.

Wang B, Gogia B, Fuller GN, Ketonen LM.

J Neuroimaging. 2018 Sep;28(5):483-489. doi: 10.1111/jon.12524. Epub 2018 May 24.

PMID:
29797626
21.

Renal cell carcinoma brain metastasis with pseudoprogression and radiation necrosis on nivolumab after previous treatment with stereotactic radiosurgery: An illustrative case report and review of the literature.

Lewis GD, Jonasch E, Shah AY, Fuller GN, Farach AM, Butler EB, Teh BS.

Pract Radiat Oncol. 2018 Sep - Oct;8(5):e262-e265. doi: 10.1016/j.prro.2018.03.003. Epub 2018 Mar 10. Review. No abstract available.

PMID:
29706304
22.

Glioblastoma stem cell-derived exosomes induce M2 macrophages and PD-L1 expression on human monocytes.

Gabrusiewicz K, Li X, Wei J, Hashimoto Y, Marisetty AL, Ott M, Wang F, Hawke D, Yu J, Healy LM, Hossain A, Akers JC, Maiti SN, Yamashita S, Shimizu Y, Dunner K, Zal MA, Burks JK, Gumin J, Nwajei F, Rezavanian A, Zhou S, Rao G, Sawaya R, Fuller GN, Huse JT, Antel JP, Li S, Cooper L, Sulman EP, Chen C, Geula C, Kalluri R, Zal T, Heimberger AB.

Oncoimmunology. 2018 Jan 16;7(4):e1412909. doi: 10.1080/2162402X.2017.1412909. eCollection 2018.

23.

FGFR1 tyrosine kinase domain duplication in pilocytic astrocytoma with anaplasia.

Ballester LY, Penas-Prado M, Leeds NE, Huse JT, Fuller GN.

Cold Spring Harb Mol Case Stud. 2018 Apr 2;4(2). pii: a002378. doi: 10.1101/mcs.a002378. Print 2018 Apr.

24.

Creutzfeldt astrocytes may be seen in IDH-wildtype glioblastoma and retain expression of DNA repair and chromatin binding proteins.

Ballester LY, Boghani Z, Baskin DS, Britz GW, Olsen R, Fuller GN, Powell SZ, Cykowski MD.

Brain Pathol. 2018 Nov;28(6):1012-1019. doi: 10.1111/bpa.12604. Epub 2018 Apr 25.

PMID:
29509313
25.

Phase I Study of DNX-2401 (Delta-24-RGD) Oncolytic Adenovirus: Replication and Immunotherapeutic Effects in Recurrent Malignant Glioma.

Lang FF, Conrad C, Gomez-Manzano C, Yung WKA, Sawaya R, Weinberg JS, Prabhu SS, Rao G, Fuller GN, Aldape KD, Gumin J, Vence LM, Wistuba I, Rodriguez-Canales J, Villalobos PA, Dirven CMF, Tejada S, Valle RD, Alonso MM, Ewald B, Peterkin JJ, Tufaro F, Fueyo J.

J Clin Oncol. 2018 May 10;36(14):1419-1427. doi: 10.1200/JCO.2017.75.8219. Epub 2018 Feb 12.

26.

Dexamethasone-mediated oncogenicity in vitro and in an animal model of glioblastoma.

Luedi MM, Singh SK, Mosley JC, Hassan ISA, Hatami M, Gumin J, Andereggen L, Sulman EP, Lang FF, Stueber F, Fuller GN, Colen RR, Zinn PO.

J Neurosurg. 2018 Dec 1;129(6):1446-1455. doi: 10.3171/2017.7.JNS17668.

PMID:
29328002
27.

Primary Central Nervous System Lymphoma With Light Chain Deposition Disease (Aggregoma).

Boulter TD, Sadaka A, Nakawah MO, Smith SV, Alouch N, Berry SE, Whyte AT, Fuller GN, Lee AG.

J Neuroophthalmol. 2018 Jun;38(2):195-197. doi: 10.1097/WNO.0000000000000612. No abstract available.

PMID:
29280764
28.

Extending the Neuroanatomic Territory of Diffuse Midline Glioma, K27M Mutant: Pineal Region Origin.

Gilbert AR, Zaky W, Gokden M, Fuller CE, Ocal E, Leeds NE, Fuller GN.

Pediatr Neurosurg. 2018;53(1):59-63. doi: 10.1159/000481513. Epub 2017 Nov 4.

PMID:
29131126
29.

Multimodality Management of Recurrent Skull Base Chordomas: Factors Impacting Tumor Control and Disease-Specific Survival.

Raza SM, Bell D, Freeman JL, Grosshans DR, Fuller GN, DeMonte F.

Oper Neurosurg (Hagerstown). 2018 Aug 1;15(2):131-143. doi: 10.1093/ons/opx201.

PMID:
29040778
30.

Transcriptome comparison identifies potential biomarkers of spine and skull base chordomas.

Bell AH, DeMonte F, Raza SM, Rhines LD, Tatsui CE, Prieto VG, Fuller GN, Bell D.

Virchows Arch. 2018 Mar;472(3):489-497. doi: 10.1007/s00428-017-2224-x. Epub 2017 Aug 27.

PMID:
28844110
31.

HNF1B Loss Exacerbates the Development of Chromophobe Renal Cell Carcinomas.

Sun M, Tong P, Kong W, Dong B, Huang Y, Park IY, Zhou L, Liu XD, Ding Z, Zhang X, Bai S, German P, Powell R, Wang Q, Tong X, Tannir NM, Matin SF, Rathmell WK, Fuller GN, McCutcheon IE, Walker CL, Wang J, Jonasch E.

Cancer Res. 2017 Oct 1;77(19):5313-5326. doi: 10.1158/0008-5472.CAN-17-0986. Epub 2017 Aug 14.

32.

Molecular classification of adult diffuse gliomas: conflicting IDH1/IDH2, ATRX, and 1p/19q results.

Ballester LY, Huse JT, Tang G, Fuller GN.

Hum Pathol. 2017 Nov;69:15-22. doi: 10.1016/j.humpath.2017.05.005. Epub 2017 May 23.

PMID:
28549927
33.

Percentage of mesenchymal stem cells in high-grade glioma tumor samples correlates with patient survival.

Shahar T, Rozovski U, Hess KR, Hossain A, Gumin J, Gao F, Fuller GN, Goodman L, Sulman EP, Lang FF.

Neuro Oncol. 2017 May 1;19(5):660-668. doi: 10.1093/neuonc/now239.

34.

Retrospective Analysis of Molecular and Immunohistochemical Characterization of 381 Primary Brain Tumors.

Ballester LY, Fuller GN, Powell SZ, Sulman EP, Patel KP, Luthra R, Routbort MJ.

J Neuropathol Exp Neurol. 2017 Mar 1;76(3):179-188. doi: 10.1093/jnen/nlw119.

PMID:
28395087
36.

Serum microRNA profiling in patients with glioblastoma: a survival analysis.

Zhao H, Shen J, Hodges TR, Song R, Fuller GN, Heimberger AB.

Mol Cancer. 2017 Mar 11;16(1):59. doi: 10.1186/s12943-017-0628-5.

37.

Isolated Ectopic Cutaneous Atypical Meningioma of the Scalp: Another Mimicker of Primary Adnexal Tumor.

Konopinski J, Prieto VG, Ivan D, Nagarajan P, Tetzlaff MT, Curry JL, Torres-Cabala CA, Fuller GN, Aung PP.

Am J Dermatopathol. 2017 Jul;39(7):545-547. doi: 10.1097/DAD.0000000000000821.

PMID:
28178009
38.

Practical Neurology reader survey 2016.

Fuller GN, Smith PE.

Pract Neurol. 2016 Dec;16(6):428-430. doi: 10.1136/practneurol-2016-001529. No abstract available.

PMID:
28120787
39.

Epigenetic Activation of WNT5A Drives Glioblastoma Stem Cell Differentiation and Invasive Growth.

Hu B, Wang Q, Wang YA, Hua S, Sauvé CG, Ong D, Lan ZD, Chang Q, Ho YW, Monasterio MM, Lu X, Zhong Y, Zhang J, Deng P, Tan Z, Wang G, Liao WT, Corley LJ, Yan H, Zhang J, You Y, Liu N, Cai L, Finocchiaro G, Phillips JJ, Berger MS, Spring DJ, Hu J, Sulman EP, Fuller GN, Chin L, Verhaak RGW, DePinho RA.

Cell. 2016 Nov 17;167(5):1281-1295.e18. doi: 10.1016/j.cell.2016.10.039.

40.

Qki deficiency maintains stemness of glioma stem cells in suboptimal environment by downregulating endolysosomal degradation.

Shingu T, Ho AL, Yuan L, Zhou X, Dai C, Zheng S, Wang Q, Zhong Y, Chang Q, Horner JW, Liebelt BD, Yao Y, Hu B, Chen Y, Fuller GN, Verhaak RG, Heimberger AB, Hu J.

Nat Genet. 2017 Jan;49(1):75-86. doi: 10.1038/ng.3711. Epub 2016 Nov 14.

41.

Fulminant spinal cord compression caused by postradiation inflammatory pseudotumor with rapid response to steroids: case report.

Verla T, Thomas JG, Thomazy V, Fuller GN, Shaibani A, Omeis I.

J Neurosurg Spine. 2016 Nov;25(5):660-664. Epub 2016 May 27.

PMID:
27231814
42.

Sarcoma Brain Metastases: 28 Years of Experience at a Single Institution.

Al Sannaa G, Watson KL, Olar A, Wang WL, Fuller GN, McCutcheon I, Torres KE, Lazar AJ.

Ann Surg Oncol. 2016 Dec;23(Suppl 5):962-967. Epub 2016 Sep 19.

PMID:
27646022
43.

Tipping a favorable CNS intratumoral immune response using immune stimulation combined with inhibition of tumor-mediated immune suppression.

Kong LY, Wei J, Fuller GN, Schrand B, Gabrusiewicz K, Zhou S, Rao G, Calin G, Gilboa E, Heimberger AB.

Oncoimmunology. 2015 Dec 21;5(5):e1117739. doi: 10.1080/2162402X.2015.1117739. eCollection 2016 May.

44.

Whole-transcriptome analysis of chordoma of the skull base.

Bell D, Raza SM, Bell AH, Fuller GN, DeMonte F.

Virchows Arch. 2016 Oct;469(4):439-49. doi: 10.1007/s00428-016-1985-y. Epub 2016 Jul 11.

PMID:
27401718
45.

Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies.

Garber ST, Hashimoto Y, Weathers SP, Xiu J, Gatalica Z, Verhaak RG, Zhou S, Fuller GN, Khasraw M, de Groot J, Reddy SK, Spetzler D, Heimberger AB.

Neuro Oncol. 2016 Oct;18(10):1357-66. doi: 10.1093/neuonc/now132. Epub 2016 Jul 1.

46.

PINK1 Is a Negative Regulator of Growth and the Warburg Effect in Glioblastoma.

Agnihotri S, Golbourn B, Huang X, Remke M, Younger S, Cairns RA, Chalil A, Smith CA, Krumholtz SL, Mackenzie D, Rakopoulos P, Ramaswamy V, Taccone MS, Mischel PS, Fuller GN, Hawkins C, Stanford WL, Taylor MD, Zadeh G, Rutka JT.

Cancer Res. 2016 Aug 15;76(16):4708-19. doi: 10.1158/0008-5472.CAN-15-3079. Epub 2016 Jun 20.

47.

Glioma progression is mediated by an addiction to aberrant IGFBP2 expression and can be blocked using anti-IGFBP2 strategies.

Phillips LM, Zhou X, Cogdell DE, Chua CY, Huisinga A, R Hess K, Fuller GN, Zhang W.

J Pathol. 2016 Jul;239(3):355-64. doi: 10.1002/path.4734. Epub 2016 Jun 10.

48.

Analysis of the inhibitors of apoptosis identifies BIRC3 as a facilitator of malignant progression in glioma.

Gressot LV, Doucette T, Yang Y, Fuller GN, Manyam G, Rao A, Latha K, Rao G.

Oncotarget. 2017 Feb 21;8(8):12695-12704. doi: 10.18632/oncotarget.8657.

49.

Cdc2-like kinase 2 is a key regulator of the cell cycle via FOXO3a/p27 in glioblastoma.

Park SY, Piao Y, Thomas C, Fuller GN, de Groot JF.

Oncotarget. 2016 May 3;7(18):26793-805. doi: 10.18632/oncotarget.8471.

50.

Driver or passenger effects of augmented c-Myc and Cdc20 in gliomagenesis.

Ji P, Zhou X, Liu Q, Fuller GN, Phillips LM, Zhang W.

Oncotarget. 2016 Apr 26;7(17):23521-9. doi: 10.18632/oncotarget.8080.

Supplemental Content

Loading ...
Support Center